Emend (aprepitant), a P/neurokinin 1 (NK1) receptor antagonist, is an antiemetic medicine used to prevent and control nausea and vomiting caused by chemotherapy treatment. It is always used in combination with other antiemetic agents.
Emend is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Emend capsules for oral administration contains either 80 mg or 125 mg of aprepitant
EMEND Rx
Nausea Only 4 drugs may be compared at once
Remove Selected
Compare Selected
Generic Name and Formulations:
Aprepitant 40mg, 80mg, 125mg; caps.
Company:
Merck & Co. Inc.
Select therapeutic use:
Nausea
Indications for EMEND:
In combination with other antiemetic agents, in patients ≥12yrs of age for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin. Prevention of post-op nausea and vomiting (PONV) in adults.
Adult:
Swallow caps whole. Chemotherapy induced: ≥12yrs: give with corticosteroid and 5-HT3 antagonist (see full labeling). 125mg on Day 1; then 80mg on Days 2 and 3. Administer caps 1 hr prior to chemotherapy on Days 1, 2, and 3; if no chemotherapy is given on Days 2 and 3, administer caps in the AM. PONV: ≥18yrs: 40mg within 3hrs prior to anesthesia.
Children:
Chemotherapy induced: <12yrs: use other oral forms. PONV: <18yrs: not established.
Contraindications:
Concomitant pimozide, cisapride.
Warnings/Precautions:
Not for chronic continuous use. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.
Interactions:
See Contraindications. Monitor, and caution with, CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine); CYP3A4 inhibitors (eg, azole antifungals, macrolides, nefazodone, ritonavir, nelfinavir, diltiazem); and with CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each regimen); phenytoin, tolbutamide, other CYP2C9 substrates; paroxetine, oral contraceptives (use alternative or backup method during and for 1 month after last dose).
See Also:
EMEND INJECTION
Pharmacological Class:
Substance P/NK1 receptor antagonist.
Adverse Reactions:
Fatigue, diarrhea, asthenia, dyspepsia, abdominal pain, hiccups, WBC count decreased, dehydration, ALT/AST increased, neutropenia, headache, anorexia, cough, hemoglobin decreased, dizziness, constipation, hypotension. Injection: inj site pain.
Generic Availability:
NO
How Supplied:
Caps 40mg—1; Bi-fold pack (2 x 80mg)—1; Tri-fold pack (1 x 125mg + 2 x 80mg)—1; Vial—1 |
